| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Riitta Törrönen, Essi Sarkkinen, Tarja Niskanen, Niina Tapola, Kyllikki Kilpi, Leo Niskane. Postprandial glucose, insulin and glucagon-like peptide 1 responses to sucrose ingested with berries in healthy subjects. The British journal of nutrition. vol 107. issue 10. 2012-07-10. PMID:21929838. |
glucose, insulin and glp-1 concentrations were determined from the venous samples, and glucose also from the capillary samples. |
2012-07-10 |
2023-08-12 |
human |
| Riitta Törrönen, Essi Sarkkinen, Tarja Niskanen, Niina Tapola, Kyllikki Kilpi, Leo Niskane. Postprandial glucose, insulin and glucagon-like peptide 1 responses to sucrose ingested with berries in healthy subjects. The British journal of nutrition. vol 107. issue 10. 2012-07-10. PMID:21929838. |
compared to the control meal, ingestion of the berry meal resulted in lower capillary and venous plasma glucose and serum insulin concentrations at 15 min (p = 0·021, p < 0·007 and p = 0·028, respectively), in higher concentrations at 90 min (p = 0·028, p = 0·021 and p = 0·042, respectively), and in a modest effect on the glp-1 response (p = 0·05). |
2012-07-10 |
2023-08-12 |
human |
| Marcus Lind, Johan Jendle, Ole Torffvit, Ibe Lage. Glucagon-like peptide 1 (GLP-1) analogue combined with insulin reduces HbA1c and weight with low risk of hypoglycemia and high treatment satisfaction. Primary care diabetes. vol 6. issue 1. 2012-07-10. PMID:22015237. |
glucagon-like peptide 1 (glp-1) analogue combined with insulin reduces hba1c and weight with low risk of hypoglycemia and high treatment satisfaction. |
2012-07-10 |
2023-08-12 |
Not clear |
| Marcus Lind, Johan Jendle, Ole Torffvit, Ibe Lage. Glucagon-like peptide 1 (GLP-1) analogue combined with insulin reduces HbA1c and weight with low risk of hypoglycemia and high treatment satisfaction. Primary care diabetes. vol 6. issue 1. 2012-07-10. PMID:22015237. |
to evaluate the effects of adding glucagon-like peptide-1 (glp-1) analogue therapy to insulin on glycated hemoglobin (hba1c), weight, insulin dosage, treatment satisfaction, and risk of hypoglycaemia. |
2012-07-10 |
2023-08-12 |
Not clear |
| Giuseppe Derosa, Pamela Maffiol. Dipeptidyl peptidase-4 inhibitors: 3 years of experience. Diabetes technology & therapeutics. vol 14. issue 4. 2012-07-09. PMID:22324384. |
through the inhibition of dpp-4, dpp-4 inhibitors enhance the effects of glp-1 and glucose-dependent insulinotropic peptide, increasing glucose-mediated insulin secretion and suppressing glucagon secretion. |
2012-07-09 |
2023-08-12 |
Not clear |
| Ruben Rodriguez, Jose A Viscarra, Jacqueline N Minas, Daisuke Nakano, Akira Nishiyama, Rudy M Orti. Angiotensin receptor blockade increases pancreatic insulin secretion and decreases glucose intolerance during glucose supplementation in a model of metabolic syndrome. Endocrinology. vol 153. issue 4. 2012-07-09. PMID:22355070. |
arb treatment in oletf arb and oletf hg/arb did not have an effect on insulin signaling proteins in skeletal muscle; however, it reduced pancreatic at₁ protein expression 20 and 27%, increased pancreatic glucagon-like peptide-1 (glp-1) receptor protein expression 41 and 88%, respectively, and increased fasting plasma glp-1 approximately 2.5-fold in oletf arb. |
2012-07-09 |
2023-08-12 |
rat |
| Ruben Rodriguez, Jose A Viscarra, Jacqueline N Minas, Daisuke Nakano, Akira Nishiyama, Rudy M Orti. Angiotensin receptor blockade increases pancreatic insulin secretion and decreases glucose intolerance during glucose supplementation in a model of metabolic syndrome. Endocrinology. vol 153. issue 4. 2012-07-09. PMID:22355070. |
the results suggest that improvement of glucose intolerance is independent of an improvement in muscle insulin signaling, but rather by improved glucose-stimulated insulin secretion associated with decreased pancreatic at₁ activation and increased glp-1 signaling. |
2012-07-09 |
2023-08-12 |
rat |
| Alan J Garbe. Incretin therapy--present and future. The review of diabetic studies : RDS. vol 8. issue 3. 2012-06-28. PMID:22262069. |
the ultimate goal of agents within both of these classes is to increase glp-1 signaling, which results in augmented glucose-induced insulin secretion, inhibition of glucagon secretion, and decreased appetite. |
2012-06-28 |
2023-08-12 |
Not clear |
| Michael Lehrke, Nikolaus Mar. Cardiovascular effects of incretin-based therapies. The review of diabetic studies : RDS. vol 8. issue 3. 2012-06-28. PMID:22262075. |
also, glp-1 augments the left ventricular function in dilative and metabolic cardiomyopathy, possibly by increasing insulin independent cardiomyocyte glucose uptake. |
2012-06-28 |
2023-08-12 |
human |
| Cendrine Cabou, Rémy Burceli. GLP-1, the gut-brain, and brain-periphery axes. The review of diabetic studies : RDS. vol 8. issue 3. 2012-06-28. PMID:22262078. |
glucagon-like peptide 1 (glp-1) is a gut hormone which directly binds to the glp-1 receptor located at the surface of the pancreatic β-cells to enhance glucose-induced insulin secretion. |
2012-06-28 |
2023-08-12 |
Not clear |
| Cendrine Cabou, Rémy Burceli. GLP-1, the gut-brain, and brain-periphery axes. The review of diabetic studies : RDS. vol 8. issue 3. 2012-06-28. PMID:22262078. |
in this environment, glp-1 is assumed to control numerous metabolic and cardiovascular functions such as insulin secretion, glucose production and utilization, and arterial blood flow. |
2012-06-28 |
2023-08-12 |
Not clear |
| Galina Smushkin, Matheni Sathananthan, Airani Sathananthan, Chiara Dalla Man, Francesco Micheletto, Alan R Zinsmeister, Claudio Cobelli, Adrian Vell. Diabetes-associated common genetic variation and its association with GLP-1 concentrations and response to exogenous GLP-1. Diabetes. vol 61. issue 5. 2012-06-28. PMID:22461567. |
in nondiabetic subjects, diabetes-associated genetic variation does not alter glp-1 concentrations after an oral challenge or its effect on insulin secretion. |
2012-06-28 |
2023-08-12 |
human |
| Sten Madsba. Dipeptidyl peptidase-4 (DPP-4) inhibitors are favourable to glucagon-like peptide-1 (GLP-1) agonists: no. European journal of internal medicine. vol 23. issue 2. 2012-06-26. PMID:22284242. |
incretin-based therapies, which include the glp-1 receptor agonists and dpp-4 inhibitors, use the antidiabetic properties of potentiating the glp-1 receptor signalling via the regulation of insulin and glucagon secretion, inhibition of gastric emptying and suppression of appetite. |
2012-06-26 |
2023-08-12 |
Not clear |
| Sten Madsba. Dipeptidyl peptidase-4 (DPP-4) inhibitors are favourable to glucagon-like peptide-1 (GLP-1) agonists: no. European journal of internal medicine. vol 23. issue 2. 2012-06-26. PMID:22284242. |
furthermore, the glp-1 receptor agonists cover the whole spectrum of treatment from time of diagnosis with lifestyle treatment to combination treatment with basal insulin. |
2012-06-26 |
2023-08-12 |
Not clear |
| Hagai Ligumsky, Ido Wolf, Shira Israeli, Michal Haimsohn, Sarah Ferber, Avraham Karasik, Bella Kaufman, Tami Rubine. The peptide-hormone glucagon-like peptide-1 activates cAMP and inhibits growth of breast cancer cells. Breast cancer research and treatment. vol 132. issue 2. 2012-06-22. PMID:21638053. |
reduced glp-1 levels are observed in obesity and type 2 diabetes mellitus (t2dm) and are associated with reduced insulin secretion and increased insulin resistance. |
2012-06-22 |
2023-08-12 |
mouse |
| K Y Thong, R E J Ryder, M L Cull, C Walto. Insulin avoidance and treatment outcomes among patients with a professional driving licence starting glucagon-like peptide 1 (GLP-1) agonists in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide and liraglutide audits. Diabetic medicine : a journal of the British Diabetic Association. vol 29. issue 5. 2012-06-22. PMID:21988449. |
insulin avoidance and treatment outcomes among patients with a professional driving licence starting glucagon-like peptide 1 (glp-1) agonists in the association of british clinical diabetologists (abcd) nationwide exenatide and liraglutide audits. |
2012-06-22 |
2023-08-12 |
Not clear |
| J Ma, A N Pilichiewicz, C Feinle-Bisset, J M Wishart, K L Jones, M Horowitz, C K Rayne. Effects of variations in duodenal glucose load on glycaemic, insulin, and incretin responses in type 2 diabetes. Diabetic medicine : a journal of the British Diabetic Association. vol 29. issue 5. 2012-06-22. PMID:22004512. |
we evaluated blood glucose, and plasma insulin, glp-1 and glucose-dependent insulinotropic polypeptide (gip) responses to intraduodenal glucose in type 2 diabetes, and compared these with data from healthy controls. |
2012-06-22 |
2023-08-12 |
Not clear |
| Koji Nakashima, Masashi Shimoda, Sumiko Hamamoto, Fuminori Tatsumi, Hidenori Hirukawa, Kazuhito Tawaramoto, Yukiko Kanda, Kohei Kak. Self-inducible secretion of glucagon-like peptide-1 (GLP-1) that allows MIN6 cells to maintain insulin secretion and insure cell survival. Molecular and cellular endocrinology. vol 349. issue 2. 2012-06-20. PMID:22108438. |
self-inducible secretion of glucagon-like peptide-1 (glp-1) that allows min6 cells to maintain insulin secretion and insure cell survival. |
2012-06-20 |
2023-08-12 |
Not clear |
| Koji Nakashima, Masashi Shimoda, Sumiko Hamamoto, Fuminori Tatsumi, Hidenori Hirukawa, Kazuhito Tawaramoto, Yukiko Kanda, Kohei Kak. Self-inducible secretion of glucagon-like peptide-1 (GLP-1) that allows MIN6 cells to maintain insulin secretion and insure cell survival. Molecular and cellular endocrinology. vol 349. issue 2. 2012-06-20. PMID:22108438. |
the confocal laser scanning images revealed that glp-1 positive cells were dominant in the early stage of cells, but positive for insulin were more prominent in the mature stage of cells. |
2012-06-20 |
2023-08-12 |
Not clear |
| Koji Nakashima, Masashi Shimoda, Sumiko Hamamoto, Fuminori Tatsumi, Hidenori Hirukawa, Kazuhito Tawaramoto, Yukiko Kanda, Kohei Kak. Self-inducible secretion of glucagon-like peptide-1 (GLP-1) that allows MIN6 cells to maintain insulin secretion and insure cell survival. Molecular and cellular endocrinology. vol 349. issue 2. 2012-06-20. PMID:22108438. |
min6 cells possess a mechanism of glp-1 signal amplification in an autocrine fashion, by which the cells maintained insulin production and cell survival. |
2012-06-20 |
2023-08-12 |
Not clear |